T

The Urology Center of Colorado | Denver, CO

Research site
(Unclaimed)
Location
2777 Mile High Stadium Circle, Denver, Colorado, United States of America

Site insights

Top conditions

Top treatments

Enzalutamide
Niraparib
Androgen
Apaziquone
Prednisone
Degarelix
Abiraterone Acetate
TAR-200
Apalutamide
Prednisone Versus Abiraterone Acetate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 59 total trials

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PROTEUS)

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectom...

Active, not recruiting
Prostatic Neoplasms
Drug: Placebo
Drug: Apalutamide

The purpose of this study is to evaluate recurrence-free survival (RFS) in participants treated with erdafitinib vs Investigator's Choice, for partic...

Active, not recruiting
Urinary Bladder Neoplasms
Drug: Investigator Choice (Gemcitabine)
Drug: Investigator Choice (Mitomycin C)

The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib comb...

Active, not recruiting
Prostatic Neoplasms, Castration-Resistant
Drug: Cetrelimab 480 mg
Drug: Niraparib 200 mg

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus predniso...

Active, not recruiting
Metastatic Castration-sensitive Prostate Cancer
Drug: Placebo for Niraparib
Drug: Niraparib

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP...

Active, not recruiting
Castration-Resistant Prostatic Cancer
Drug: Abiraterone Acetate
Drug: Placebo

The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate ca...

Active, not recruiting
Prostate Cancer
Biological: Nivolumab
Other: Placebo

The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder canc...

Active, not recruiting
Non-muscle Invasive Bladder Cancer
Drug: Bacillus Calmette-Guerin
Drug: PF-06801591

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Enrolling
Urinary Bladder Neoplasms
Drug: TAR-200
Radiation: Conventional radiation therapy

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab...

Enrolling
Urinary Bladder Neoplasms
Biological: Cetrelimab
Drug: TAR-200

This is a global, multi-center, open-label, randomized phase 1b/2, active-controlled safety and efficacy study of oral administration of tazemetostat...

Active, not recruiting
Metastatic Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Drug: Tazemetostat
Drug: Abiraterone/prednisone

The ProVent study is a randomized, open-label study designed to assess the efficacy of sipuleucel-T in reducing the progression of lower risk non-met...

Active, not recruiting
Adenocarcinoma of the Prostate
Biological: sipuleucel-T

The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radica...

Active, not recruiting
Hormone Sensitive Prostate Cancer
Prostate Cancer
Drug: Enzalutamide
Drug: Placebo (No longer applicable in Open Label study period)

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and...

Enrolling
Cancer
Drug: Darolutamide (Nubeqa, BAY1841788)

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of tal...

Active, not recruiting
mCRPC
Drug: Talazoparib with enzalutamide
Drug: Placebo with enzalutamide

Trial sponsors

J
D
Ferring logo
Pfizer logo
Spectrum Pharmaceuticals logo
Endo Pharmaceuticals logo
Bayer logo
P
Allergan logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems